Payment overview · 2025
General Payments
$1,532.24
57 reported records · 16 companies
Healthcare provider profile · identity verified
Remya James, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · NEW BRUNSWICK, NJ · NPI 1497310544
Verified facts
What the public records show
CMS Open Payments records show Remya James, APN received $1,532.24 in general payments during 2025 across 57 reported records.
Tactile Systems Technology Inc accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $295.91 | 19.3% | 6 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $242.36 | 15.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $194.76 | 12.7% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $173.40 | 11.3% | 12 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $149.68 | 9.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.32 | 5.8% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $86.77 | 5.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.22 | 4.1% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $53.96 | 3.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.44 | 3.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.06 | 3.0% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $22.86 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.88 | 1.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.33 | 1.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $16.27 | 1.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $16.02 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,385.56 | 56 |
| Long term medical supply or device loan | $146.68 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $295.91 | 6 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $295.91 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $194.76 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $173.40 | 12 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $149.68 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $149.68 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $149.68 | 1 | 2025 |
Source payment records
|
|||||
| MicroMatrix Normalized: micromatrix |
Device | Integra LifeSciences Corporation | $146.68 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $133.21 | 8 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $95.68 | 3 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $95.68 | 3 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $95.68 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.80 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $53.96 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.06 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.80 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.52 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 296 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 52 |
| Losartan Potassium | Losartan Potassium | 105 | 25 |
| Metformin Hcl | Metformin Hcl | 100 | 24 |
| Vascepa | Icosapent Ethyl | 91 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 25 |
| Lisinopril | Lisinopril | 82 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 17 |
| Omeprazole | Omeprazole | 75 | 16 |
| Simvastatin | Simvastatin | 69 | 16 |
| Famotidine | Famotidine | 60 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 13 |
| Gabapentin | Gabapentin | 50 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 16 |
| Montelukast Sodium | Montelukast Sodium | 47 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 12 |
| Finasteride | Finasteride | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 16 |
| Linzess | Linaclotide | 36 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 13 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Naproxen | Naproxen | 26 | 13 |
| Alprazolam | Alprazolam | 24 | 11 |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Carvedilol | Carvedilol | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Lorazepam | Lorazepam | 23 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Nystatin | Nystatin | 20 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Nicotrol Ns | Nicotine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,532.24 · 57 records | Tactile Systems Technology Inc | AFFINITY, APLIGRAF, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Flexitouch Plus, Integra, Integra Dermal Regeneration Template, LEQEMBI, MicroMatrix, Nimbl, OTEZLA, Ozempic, PRIMATRIX, PURAPLY WOUND MATRIX, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error